SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS
Delisted
SYRS was delisted on the 19th of March, 2025.
45 hedge funds and large institutions have $205M invested in Syros Pharmaceuticals, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
45
Holders Change
+3
Holders Change %
+7.14%
% of All Funds
1.12%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
14
Reduced
8
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
BlackRock
New York
|
$2.86M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
$2.1M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
$400K |
| 4 |
State Street
Boston,
Massachusetts
|
$976K |
| 5 |
Wells Fargo
San Francisco,
California
|
$225K |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
$25.7M |
| 2 |
Morgan Stanley
New York
|
$173K |
| 3 |
Goldman Sachs
New York
|
$0 |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
$637K |
| 5 |
JPMorgan Chase & Co
New York
|
$1.92M |
